What is BLFS's P/E ratio?

BIOLIFE SOLUTIONS INC (BLFS) currently trades at a P/E ratio of 289.38.

BIOLIFE SOLUTIONS INC reports a Return on Equity (ROE) of -2.82%.

What is BLFS's dividend yield?

BIOLIFE SOLUTIONS INC offers a dividend yield of 0.00%.

What is BLFS's Quality Score?

Our AI rates BLFS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy BLFS?

Our AI Timing Score for BLFS is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does BLFS belong to?

BIOLIFE SOLUTIONS INC is classified under the Healthcare >> Medical Instruments & Supplies sector on the NASDAQ exchange

BLFS (NASDAQ) Stock Analysis | BIOLIFE SOLUTIONS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

BLFS AI Analysis Summary

Our AI summary for BLFS: BIOLIFE SOLUTIONS INC (NASDAQ), Healthcare >> Medical Instruments & Supplies sector. The stock currently trades at a P/E of 289.38, ROE of -2.82%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

BLFS

BIOLIFE SOLUTIONS INC

USD 31.28

-0.36 (-1.14%) Day Change

Watchlist Portfolio Compare Chart

289.38

P/E

0.01

D/E

-2.8%

ROE

-2.6%

ROA

0.00%

Div Yield

-5.16

PEG

BIOLIFE SOLUTIONS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 31.28 Price -0.36 (-1.14%) Day Change	NEWS SCORE: 94

BLFS, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	94
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	31.28
PBV / Sector	4.15 / 3.37
Earning Per Share	-0.21

PE / Sector	289.38 / 44.25
PEG or PE/Growth / Sector	-5.16 / -1.35
Average 1M Daily Value	47.43 M GREAT
Average 1W Daily Value	37.71 M GREAT

Timing Factors

85%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

54%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-10.52 / 82.17
NPM Average (%) / Sector	-63.72 / 28.91
NPM Change Average (%) / Sector	-47.35 / 208.28
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-2.62 / 7.70
ROA Average (%) / Sector	-11.56 / -22.17
ROA Change Average (%) / Sector	-42.51 / 105.15
ROE (%) / Sector	-2.82 / 10.10
ROE Average (%) / Sector	-13.99 / 392.40
ROE Change Average (%) / Sector	-44.13 / 109.80
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.99
Dividend Average (%) / Sector	N/A / 1.43
Dividend Change Average (%) / Sector	N/A / 11.29

Registration Details

Analyze Date	2026-08-01 07:59:33
Symbol	BLFS
Name	BIOLIFE SOLUTIONS INC
Sector	Healthcare >> Medical Instruments & Supplies
Market	NASDAQ
Listed Shares	48.86 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,545.85 / 16,159.14

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3303 Monte Villa Parkway, Bothell, WA, United States, 98021

Phone: 425 402 1400

Website: https://www.biolifesolutions.com

Employees: 155

Sector: Healthcare >> Medical Instruments & Supplies

Description: BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.